Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multi-center, Randomized Withdrawal and Long Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants With Multiple System Atrophy

NCT05696717 is registered in ClinicalTrials.gov with Theravance Biopharma as lead sponsor.

NCT NCT05696717
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05696717 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multi-center, Randomized Withdrawal and Long Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants With Multiple System Atrophy
Lead sponsor
Theravance Biopharma
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 27, 2023
Completion date
January 31, 2028
Enrollment
102 (estimated)
Sites
79

Conditions

As the registry lists them; a condition with its own page is linked.

msa - multiple system atrophy, symptomatic neurogenic orthostatic hypotension